🔎 Trials Near Me

Home › Fractures › NCT07920484

A Clinical Study to Collect Real-wordt Data on Safety and Clinical Performance of the VCFix Spinal System for Treatment of Vertebral Compression Fractures of (Suspected) Osteoporotic Origin.

RecruitingObservational study

A Prospective, Multicenter, Post-Market Clinical Study Collecting Real-World Data of the VCFix Spinal System in Stand-Alone Configuration for Vertebral Augmentation (EXPAND-US)

Who can join

Ages 21 to 85 · All sexes

Full eligibility criteria
Inclusion Criteria:

* 1\. Subject is ≥ 21 to ≤ 85 years old. 2.

Single vertebral fracture which meets all of the following criteria:

* Type A fractures from AO spine classification (compression injuries);
* Vertebral fracture located in the thoracic and lumbar regions of the spine
* Fracture age \< 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history)
* Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence
* Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject is diagnosed with, or has a suspected diagnosis of, severe osteoporosis, including low trabecular bone quality , and/or an oversized vertebral body as compared to implant size (e.g. relatively small pedicle requiring smaller implant size than desired for vertebral body size and/or fracture characteristics and location) 4. Subject has a NPRS back pain score of ≥5 5. Subject is a candidate for surgical intervention based on investigator opinion 6. Subject has a body Mass Index (BMI) \< 35 7. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 8. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent

Exclusion Criteria:

1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal
2. Non-mobile fractures (i.e., fracture is not recent (\>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction).
3. Spondylolisthesis \> Grade 1 at target vertebral body(s)
4. Local kyphotic angle \> 30°
5. Any pre-existing vertebral fracture prior to the index fracture
6. Previous spine surgery, balloon kyphoplasty or vertebroplasty, for any vertebral fracture
7. Subjects that require anterior stabilization of the index fracture
8. Fracture to the pedicle based on radiographic evaluation
9. Spinal cord compression or canal compromise requiring decompression
10. Severe back pain due to causes other than acute fracture with NPRS score \> 5
11. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
12. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication
13. Pre-existing neurological deficit, radiculopathy or myelopathy
14. Pre-existing condition or significant co-morbidity:

    1. Uncontrolled diabetes (HbA1c \>8%)
    2. Severe cardiopulmonary deficiencies
    3. Any other condition that would impact study outcome in the opinion of the investigator
15. Irreversible coagulopathy or bleeding disorder
16. Contraindications to both MRI and Computed Tomography (CT) imaging
17. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study
18. A life expectancy less than the study duration or undergoing palliative care
19. Subject non-ambulatory prior to fracture Allergy to any components of the device/instruments used during the procedure
20. Allergy to any components of the device/instruments used during the procedure
21. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
22. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.)
23. Any evidence of alcohol or drug abuse
24. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for \>3 months)
25. The subject is currently on anti-cancer therapy or anti-HIV therapy
26. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration.
27. Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery

About the study

This study is designed as a prospective, post-market, multi-center, single-arm study to collect real-world data of the VCFix Spinal System used in US clinical practice.

Approximately 5 centers in the US will enroll subjects with VCF in a non-randomized fashion, and VCFix will be used within its cleared purpose and indications for use.

The study has been designed to be methodologically compatible with the EU EXPAND (CIP-VS02-EU) study, thereby aiming for the pooling of data to the EU study. Data pooling will be pursued only as a sensitivity analysis if pre-specified similarity criteria are met. The US study provides meaningful real-world evidence regardless of pooling feasibility.

The targeted patient population, assessment schedule, and study endpoints are therefore similar to those of the EU EXPAND study.

What is being tested

Sponsor: Amber Implants B.V. · Participants: 30 · Started: Oct 4, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07920484

Locations in the U.S.

New YorkMontefiore Medical Center, New York
OklahomaUniversity of Oklahoma Health Campus, Oklahoma City (Not yet recruiting)
PennsylvaniaRothman Orthopaedics, Philadelphia (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.